Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This study describes the radioiodination of an antibody specific to the vascular endothelial growth factor (VEGF), VG76e, with [124I]iodine to obtain a novel PET tracer for measurement of angiogenesis. In vitro binding assays showed a significantly higher immunoreactive fraction with the protein labelling reagent N-succinimidyl 3-(4-hydroxy-5-[125I]iodophenyl) propionate ([125I]Bolton-Hunter reagent, [125I]I-SHPP) (34.0 ± 4.0%) as compared with N-succinimidyl 3-[125I]iodobenzoate (10.9 ± 6.4%) or direct radioiodination using [125I]iodide and IodoGen (3.1 ± 3.0%). Consequently, the cyclotron-produced positron-emitting [124I]iodine (T1/2 = 4.2 days) was employed to prepare [124I]I-SHPP. Using an improved radioiodination methodology, [124I]I-SHPP was prepared from sodium [124I] iodide with IodoGen at pH 6.5. The [124I]Bolton-Hunter reagent was isolated with 25-58% (n = 3) radiochemical yield and 88-95% (n = 3) radiochemical purity by the conventional extraction procedure. The conjugate of VG76e with [124I]I-SHPP was prepared with 17-18% (n=3) labelling efficiency and 98% radiochemical purity. The immunoreactive fraction was determined to be 33.5% (n = 2). Copyright © 2002 John Wiley & Sons, Ltd.

Original publication

DOI

10.1002/jlcr.634

Type

Journal article

Journal

Journal of Labelled Compounds and Radiopharmaceuticals

Publication Date

30/10/2002

Volume

45

Pages

1077 - 1090